Improved antibacterial function of Rifampicin-loaded solid lipid nanoparticles on Brucella abortus
Source abstract
Abstract
The objective of this study was to assess the antibacterial activity of Rifampicin-loaded solid lipid nanoparticles on Brucella abortus 544. Rifampicin-loaded solid lipid nanoparticles were prepared by a modified microemulsion/sonication method and characterized. The results showed the average size about 319.7 nm, PI about 0.20 and zeta potential about 18.4 mv, encapsulation efficacy and drug-loading were equal to 95.78 and 34.2%, respectively, with a spherical shape. Drug release lasted for 5 days. The antibacterial activity was statistically significant with p < .05 in bacterial and cell culture media compared to free Rifampicin. It can be concluded that solid lipid nanoparticles can be considered as a promising delivery system for improving the antibacterial activity of Rifampicin against Brucella abortus.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Brucella: diagnosis, epidemiology, treatment · Advancements in Transdermal Drug Delivery · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Microbiology, Hamadan University of Medical Sciences
Modeling of Noncommunicable Diseases Research Center, Department of Biostatistics and Epidemiology, School of Public Health, Hamadan University of Medical Sciences
Endometrium and Endometriosis Research Centre, Hamadan University of Medical Sciences
Department of Biochemistry, Hamadan University of Medical Sciences
Funding
Vice-Chancellor for Research and Technology, Hamadan University of Medical Sciences
References (50)
Show source-provided references
1. Farazi A, Zarrinfar N, Didgar F, et al. Risk factors for failure of treatment and relapse of brucellosis. Arak Uni Med Sci. 2014;17(4):47–53.
2. 10.1159/00023956310.1159/000239563 ↗
3. 10.1016/j.ajpath.2015.03.00310.1016/j.ajpath.2015.03.003 ↗
4. 10.1111/j.1574-6968.2009.01530.x10.1111/j.1574-6968.2009.01530.x ↗
5. 10.5539/gjhs.v8n7p7710.5539/gjhs.v8n7p77 ↗
6. Imbuluzqueta E, Gamazo C, Ariza J, et al. Drug delivery systems for potential treatment of intracellular bacterial infections. Front Biosci. 2010;65:1215–1223.
7. 10.1111/j.1472-8206.2011.00955.x10.1111/j.1472-8206.2011.00955.x ↗
8. 10.1016/j.jconrel.2007.10.02710.1016/j.jconrel.2007.10.027 ↗
9. 10.4103/ijmy.ijmy_21_1710.4103/ijmy.ijmy_21_17 ↗
10. 10.1164/rccm.200504-613PP10.1164/rccm.200504-613PP ↗
11. Lopes CPA. Development and characterization of lipid nanoparticles prepared by miniemulsion technique [dissertation]. Portugal: Technico Lisboa; 2014.
12. 10.1016/j.jconrel.2015.12.01410.1016/j.jconrel.2015.12.014 ↗
13. Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2:80–102.
14. 10.1016/j.addr.2014.02.00210.1016/j.addr.2014.02.002 ↗
15. 10.1208/s12249-015-0439-110.1208/s12249-015-0439-1 ↗
16. 10.1016/j.colsurfb.2014.02.04510.1016/j.colsurfb.2014.02.045 ↗
17. Vitthal KU, Pillai M, Kininge P. Study of solid lipid nanoparticles as a carrier for bacoside. Int J Pharma BioSci. 2013;3:414–426.
18. 10.4103/0975-1483.8376510.4103/0975-1483.83765 ↗
19. 10.1016/j.ijpharm.2013.11.03810.1016/j.ijpharm.2013.11.038 ↗
20. 10.1002/ejlt.20140065010.1002/ejlt.201400650 ↗
21. 10.3109/10837450.2013.78433610.3109/10837450.2013.784336 ↗
22. 10.5152/etd.2013.0110.5152/etd.2013.01 ↗
23. 10.1016/j.tube.2005.08.00910.1016/j.tube.2005.08.009 ↗
24. 10.1248/cpb.59.26010.1248/cpb.59.260 ↗
25. 10.1016/j.ijpharm.2013.02.01210.1016/j.ijpharm.2013.02.012 ↗
26. Lim WH, Tan YJ, Lee CS, et al. Preparation and optimization of palm-based lipid nanoparticles loaded with griseofulvin. Iran J Pharm Res. 2017;16:451.
27. 10.1186/2228-5326-2-3310.1186/2228-5326-2-33 ↗
28. 10.4081/nd.2012.e810.4081/nd.2012.e8 ↗
29. 10.1016/j.addr.2012.09.02110.1016/j.addr.2012.09.021 ↗
30. Kazemi D, Salouti M, Rostamizadeh K, et al. Development of gentamicin-loaded solid lipid nanoparticles: evaluation of drug release kinetic and antibacterial activity against Staphylococcus aureus. Int J Pharm Res Innov. 2014;7:1–6.
31. 10.2147/IJN.S1367110.2147/IJN.S13671 ↗
32. 10.1002/jbm.b.3099410.1002/jbm.b.30994 ↗
33. 10.1016/j.colsurfb.2005.08.00510.1016/j.colsurfb.2005.08.005 ↗
34. Nikam S, Chavan M, Sharma PH. Solid lipid nanoparticles: a lipid based drug delivery. Nanotechnology. 2014;1:5.
35. 10.1155/2017/598401410.1155/2017/5984014 ↗
36. 10.1615/CritRevTherDrugCarrierSyst.201501211410.1615/CritRevTherDrugCarrierSyst.2015012114 ↗
37. Wang R, Li L, Wang B, et al. FK506-loaded solid lipid nanoparticles: preparation, characterization and in vitro transdermal drug delivery. Afr J Pharm Pharmacol. 2012;6:904–913.
38. 10.2217/nnm.10.2510.2217/nnm.10.25 ↗
39. 10.1208/s12249-010-9526-510.1208/s12249-010-9526-5 ↗
40. 10.2147/IJN.S13189310.2147/IJN.S131893 ↗
41. 10.1016/j.ijpharm.2015.02.05010.1016/j.ijpharm.2015.02.050 ↗
42. 10.1016/S0378-5173(02)00220-X10.1016/S0378-5173(02)00220-X ↗
43. 10.1016/j.jddst.2017.03.02710.1016/j.jddst.2017.03.027 ↗
44. 10.1016/j.ajps.2013.10.00110.1016/j.ajps.2013.10.001 ↗
45. 10.1016/j.colsurfb.2011.03.02910.1016/j.colsurfb.2011.03.029 ↗
46. 10.1248/cpb.49.144410.1248/cpb.49.1444 ↗
47. 10.1186/s40199-015-0128-310.1186/s40199-015-0128-3 ↗
48. 10.1039/C5AY01711D10.1039/C5AY01711D ↗
49. 10.2217/nnm-2017-024810.2217/nnm-2017-0248 ↗
50. 10.29252/ibj.22.4.27510.29252/ibj.22.4.275 ↗